ClinicalTrials.gg
CompletedNCT01628848Updated Mar 19, 2014Results posted

A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients

A Phase 2 interventional study of SPM 962 and Placebo in Parkinson's Disease, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 7 sites in Japan. Open to participants aged 30 Years to 79 Years. Per ClinicalTrials.gov, last updated 2014-03-19.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
30 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
17th of 42
174 · median 123
Started
2006
with 4 others
Phase 2
7 of 44
none open now
Registered
23rd of 44
by date
Lead sponsor
7 of 44
Otsuka Pharmaceutical Co., Ltd.

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 17th largest by enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2006, is one of 7 in phase 2, and was the 23rd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 30 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

The primary objective of this study is to investigate efficacy and safety of SPM 962 in advanced Parkinson's Disease (PD) patients in a multi-center, placebo-controlled study following once-daily multiple transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg (12 weeks of dose titration/maintenance period). Recommended maintenance dose range is also to be investigated with distribution of the maintenance dose and accumulated response rate of efficacy.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • SPM 962
  • rotigotine
  • Parkinson's disease
  • concomitant use of L-dopa
04

Who can participate

Ages eligible
30 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject diagnosed as having Parkinson's disease in accordance with "Diagnostic Criteria established by the Research Committee of MHLW-specified Intractable Neurodegenerative Diseases (1995)".
  • Subject is 30 and more and less than 80 years of age at the time of .
  • Hoehn \& Yahr stage 2-4 (on time).
  • Total UPDRS Part 3 score is over 10 at screening test (on time).
  • Subject is on a stable dose of L-dopa with no change in daily dose or dosing regimen for at least 28 days prior to the initial treatment of SPM 962.
  • Subject has any of the following problematic symptoms; 1) Wearing off phenomenon 2) On and off phenomenon 3) Delayed-on and/or No-on phenomenon 4) Not well controlled with L-dopa due to adverse effect 5) Weakening of L-dopa efficacy.

Exclusion criteria

Exclusion Criteria:

  • Subject has previously participated in a trial with SPM 962.
  • Subject is on other dopamine agonist treatment within 28 days prior to the initial treatment.
  • Subject has psychiatric symptoms, e.g. confusion, hallucination, delusion, excitation, delirium, abnormal behavior at screening test or baseline.
  • Subject has orthostatic hypotension.
  • Subject has a history of epilepsy, convulsion and other.
  • Subject has a complication of serious cardiac disorder or has the history.
  • Subject has arrhythmia and treated with class 1a antiarrhythmic drugs (e.g. quinidine, procainamide etc.) or class 3 antiarrhythmic drugs (e.g. amiodarone, sotalol etc.).
  • At screening and baseline, subject develops serious abnormality. Subjects has -interval >450 msec twice at screening. Subject has a the average QTc-interval from two ECGs >450 msec in males and >470 msec in females at baseline.
  • Subject has congenital long QT syndrome.
  • Subject has hypokalaemia.
  • Subject has a total >= 3.0 mg/dL or (GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or >= 100 IU/L) at screening test.
  • Subject has BUN >= 25 mg/dL or serum creatinine >= 2.0 mg/dl at screening test.
  • Subject has a history of allergic reaction to topical agents such as transdermal patch.
  • Subject is pregnant or nursing or woman who plans pregnancy during the trial.
  • Subject is receiving therapy with prohibited drug specified in the study protocol.
  • Subject has a history of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant.
  • Subject has dementia.
  • Subject is unable to give consent.
  • Subject is participating in another trial of an drug or done so within 24 weeks prior to the initial treatment.
  • Investigator judges that subject is inappropriate as a study subject with other reasons.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
174 participants (actual)

Study arms

  • Experimental
    SPM 962

    SPM 962 transdermal patch

    Drug: SPM 962

  • Placebo comparator
    Placebo

    Placebo transdermal patch

    Drug: Placebo

Interventions

  • SPM 962 transdermal patch once a daily up to 36.0 mg/day

  • DrugPlacebo

    Placebo transdermal patch

06

What researchers measure

Primary outcomes

  1. Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score

    Mean change (LOCF) from baseline in UPDRS Part 3 sum score at 12 weeks after dosing. UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: baseline, 12 weeks after dosing

Secondary outcomes

  1. UPDRS Part 2 Sum Score (Average Score of on State and Off State)

    Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average scores of on state and off state) at 12 weeks after dosing. Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average score of on state and off state) at 12 weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: baseline, 12 weeks after dosing

  2. Off Time

    Mean change (LOCF) from baseline in off time at 12 weeks after dosing.

    Time frame: baseline, 12 weeks after dosing

  3. Effective Rate in UPDRS Part 3 Sum Score

    Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 3 sum score at 12 weeks after dosing.

    Time frame: Baseline, 12 weeks after dosing

  4. UPDRS Part 1 Sum Score

    Mean change (LOCF) from baseline in UPDRS Part 1 sum score at 12 weeks after dosing. UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, 12 weeks after dosing

  5. Effective Rate in Off Time

    Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in off time at 12 weeks after dosing.

    Time frame: Baseline, 12 weeks after dosing.

  6. UPDRS Part 2 Sum Score (on State)

    Mean change (LOCF) from baseline in UPDRS Part 2 sum score (on state) at 12 weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, 12 weeks after dosing

  7. UPDRS Part 2 Sum Score (Off State)

    Mean change (LOCF) from baseline in UPDRS Part 2 sum score (off state) at 12 weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, 12 weeks after dosing

  8. UPDRS Part 4 Sum Score

    Mean change (LOCF) from baseline in UPDRS Part 4 sum score at 12 weeks after dosing. UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, 12 weeks after dosing

  9. Total of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and UPDRS Part 3 Sum Score

    Mean change (LOCF) from baseline in total of UPDRS Part 2 sum score (average score of on state and off state), and UPDRS Part 3 sum score at 12 weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, 12 weeks after dosing

  10. Total of UPDRS Part 1 Sum Score, UPDRS Part 2 Sum Score (Average Score of on State and Off State), UPDRS Part 3 Sum Score, and UPDRS Part 4 Sum Score.

    Mean change (LOCF) from baseline in total of UPDRS Part 1 sum score, UPDRS Part 2 sum score (average score of on state and off state), UPDRS Part 3 sum score, and UPDRS Part 4 sum score at 12 weeks after dosing. UPDRS sub-scale Part 1, 2, 3, and 4 assess 4, 13, 14, and 11 items respectively. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, 12 weeks after dosing

  11. The Modified Hoehn & Yahr Severity of Illness

    Mean change (LOCF) from baseline in the Modified Hoehn \& Yahr Severity of Illness at 12 weeks after dosing. The Modified Hoehn \& Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided.

    Time frame: Baseline, 12 weeks after dosing

07

Results

Posted Mar 19, 2014

Participant flow

Participant flow — Overall Study
MilestoneSPM 962Placebo
Started8787
Completed7573
Not completed1214
Withdrew: Adverse event97
Withdrew: Lack of efficacy04
Withdrew: Withdrawal by subject02
Withdrew: Physician decision31

Outcome measures

PrimaryUnified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score

Mean change (LOCF) from baseline in UPDRS Part 3 sum score at 12 weeks after dosing. UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
baseline, 12 weeks after dosing
Reported as:
Mean · Scores on a scale
Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score
Scores on a scaleSPM 962Placebo
Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score-10.1 ± 9.0-4.4 ± 7.4
SecondaryUPDRS Part 2 Sum Score (Average Score of on State and Off State)

Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average scores of on state and off state) at 12 weeks after dosing. Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average score of on state and off state) at 12 weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
baseline, 12 weeks after dosing
Reported as:
Mean · Scores on a scale
UPDRS Part 2 Sum Score (Average Score of on State and Off State)
Scores on a scaleSPM 962Placebo
UPDRS Part 2 Sum Score (Average Score of on State and Off State)-3.8 ± 3.6-1.6 ± 2.6
SecondaryOff Time

Mean change (LOCF) from baseline in off time at 12 weeks after dosing.

Time frame:
baseline, 12 weeks after dosing
Reported as:
Mean · Hours
Off Time
HoursSPM 962Placebo
Off Time-2.1 ± 3.1-0.7 ± 2.8
SecondaryEffective Rate in UPDRS Part 3 Sum Score

Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 3 sum score at 12 weeks after dosing.

Time frame:
Baseline, 12 weeks after dosing
Reported as:
Number · Percentage of participants
Effective Rate in UPDRS Part 3 Sum Score
Percentage of participantsSPM 962Placebo
Subjects with ≥20% decrease73.3 (63.9 to 82.6)43.0 (32.6 to 53.5)
Subjects with ≥30% decrease64.0 (53.8 to 74.1)29.1 (19.5 to 38.7)
SecondaryUPDRS Part 1 Sum Score

Mean change (LOCF) from baseline in UPDRS Part 1 sum score at 12 weeks after dosing. UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, 12 weeks after dosing
Reported as:
Mean · Scores on a scale
UPDRS Part 1 Sum Score
Scores on a scaleSPM 962Placebo
UPDRS Part 1 Sum Score-0.15 ± 1.34-0.12 ± 0.79
SecondaryEffective Rate in Off Time

Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in off time at 12 weeks after dosing.

Time frame:
Baseline, 12 weeks after dosing.
Reported as:
Number · Percentage of participants
Effective Rate in Off Time
Percentage of participantsSPM 962Placebo
Subjects with ≥20% decrease63.0 (50.1 to 75.8)46.4 (33.4 to 59.5)
Subjects with ≥30% decrease51.9 (38.5 to 65.2)37.5 (24.8 to 50.2)
SecondaryUPDRS Part 2 Sum Score (on State)

Mean change (LOCF) from baseline in UPDRS Part 2 sum score (on state) at 12 weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, 12 weeks after dosing
Reported as:
Mean · Scores on a scale
UPDRS Part 2 Sum Score (on State)
Scores on a scaleSPM 962Placebo
UPDRS Part 2 Sum Score (on State)-3.0 ± 3.7-1.2 ± 2.6
SecondaryUPDRS Part 2 Sum Score (Off State)

Mean change (LOCF) from baseline in UPDRS Part 2 sum score (off state) at 12 weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, 12 weeks after dosing
Reported as:
Mean · Scores on a scale
UPDRS Part 2 Sum Score (Off State)
Scores on a scaleSPM 962Placebo
UPDRS Part 2 Sum Score (Off State)-4.6 ± 4.5-1.9 ± 3.6
SecondaryUPDRS Part 4 Sum Score

Mean change (LOCF) from baseline in UPDRS Part 4 sum score at 12 weeks after dosing. UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, 12 weeks after dosing
Reported as:
Mean · Scores on a scale
UPDRS Part 4 Sum Score
Scores on a scaleSPM 962Placebo
UPDRS Part 4 Sum Score-0.40 ± 1.73-0.22 ± 1.21
SecondaryTotal of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and UPDRS Part 3 Sum Score

Mean change (LOCF) from baseline in total of UPDRS Part 2 sum score (average score of on state and off state), and UPDRS Part 3 sum score at 12 weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, 12 weeks after dosing
Reported as:
Mean · Scores on a scale
Total of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and UPDRS Part 3 Sum Score
Scores on a scaleSPM 962Placebo
Total of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and UPDRS Part 3 Sum Score-14.0 ± 11.4-6.0 ± 9.3
SecondaryTotal of UPDRS Part 1 Sum Score, UPDRS Part 2 Sum Score (Average Score of on State and Off State), UPDRS Part 3 Sum Score, and UPDRS Part 4 Sum Score.

Mean change (LOCF) from baseline in total of UPDRS Part 1 sum score, UPDRS Part 2 sum score (average score of on state and off state), UPDRS Part 3 sum score, and UPDRS Part 4 sum score at 12 weeks after dosing. UPDRS sub-scale Part 1, 2, 3, and 4 assess 4, 13, 14, and 11 items respectively. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, 12 weeks after dosing
Reported as:
Mean · Scores on a scale
Total of UPDRS Part 1 Sum Score, UPDRS Part 2 Sum Score (Average Score of on State and Off State), UPDRS Part 3 Sum Score, and UPDRS Part 4 Sum Score.
Scores on a scaleSPM 962Placebo
Total of UPDRS Part 1 Sum Score, UPDRS Part 2 Sum Score (Average Score of on State and Off State), UPDRS Part 3 Sum Score, and UPDRS Part 4 Sum Score.-14.6 ± 11.9-6.4 ± 10.1
SecondaryThe Modified Hoehn & Yahr Severity of Illness

Mean change (LOCF) from baseline in the Modified Hoehn \& Yahr Severity of Illness at 12 weeks after dosing. The Modified Hoehn \& Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided.

Time frame:
Baseline, 12 weeks after dosing
Reported as:
Number · Percentage of participants
The Modified Hoehn & Yahr Severity of Illness
Percentage of participantsSPM 962Placebo
Increased1.24.7
Not changed61.680.0
Decreased37.215.3

Adverse events

Collected over 14 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPM 962—3/87 (3.4%)80/87 (92%)
Placebo—3/87 (3.4%)59/87 (67.8%)
Most frequent serious events
Most frequent serious events
EventSPM 962Placebo
AnaemiaBlood and lymphatic system disorders1/870/87
Hernia InguinalGastrointestinal disorders0/871/87
MalaiseGeneral disorders1/870/87
Arthritis BacterialInfections and infestations0/871/87
GastroenteritisInfections and infestations0/871/87
Blood Creatine Phosphokinase IncreasedInvestigations1/870/87
Consciousness LossNervous system disorders0/871/87
Neuroleptic MalignantNervous system disorders1/870/87
DelusionPsychiatric disorders1/870/87
Hallucination, AuditoryPsychiatric disorders1/870/87
Most frequent other events
Showing 10 of 28
Most frequent other events
EventSPM 962Placebo
Application Site ReactionGeneral disorders44/8716/87
NasopharyngitisInfections and infestations18/8713/87
NauseaGastrointestinal disorders17/875/87
DyskinesiaNervous system disorders12/877/87
SomnolencePsychiatric disorders12/871/87
ConstipationGastrointestinal disorders9/871/87
VomitingGastrointestinal disorders9/871/87
Application Site ErythemaGeneral disorders8/874/87
Hallucination VisualPsychiatric disorders8/872/87
FallInjury, poisoning and procedural complications6/877/87

Baseline characteristics

Excluded 1 sebject of each arm by vaiolation of protocol

Age, Categorical
Age, Categorical(Participants)SPM 962PlaceboTotal
<=18 years000
Between 18 and 65 years242650
>=65 years6260122
Age, Continuous
Age, Continuous(years)SPM 962PlaceboTotal
Mean67.0 ± 6.866.8 ± 8.366.9 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)SPM 962PlaceboTotal
Female524294
Male344478
Region of Enrollment
Region of Enrollment(participants)SPM 962PlaceboTotal
Japan8787174
08

Study locations

7 sites
  • Chubu Region, Japan
  • Hokkaido Region, Japan
  • Kanto Region, Japan
  • Kinki Region, Japan
  • Kyushu Region, Japan
  • Shikoku Region, Japan
  • Tohoku Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 5 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2012
First posted
Jun 27, 2012
Start
Aug 2006
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Mar 19, 2014
Last update
Mar 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01628848
Responsible party
Sponsor
First posted
Jun 27, 2012
Start date
Aug 2006
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Mar 19, 2014
Last update
Mar 19, 2014

Study contacts

Kyoji Imaoka, Mr
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion